An aberrant protein complex in CSF as a biomarker of Alzheimer disease

Neurology

Volumn 70, Issue 23, 2008, Pages 2212-2218

  Lovell, M A ^a,b,d   Lynn, B C ^a   Xiong, S ^b   Quinn, J F ^c   Kaye, J ^c   Markesbery, W R ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PREALBUMIN; PROSTAGLANDIN D SYNTHASE; ISOMERASE; LIPOCALIN; MULTIPROTEIN COMPLEX; PROSTAGLANDIN R2 D ISOMERASE; PROSTAGLANDIN R2 D-ISOMERASE;

AGED; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUMBAR PUNCTURE; MALE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; QUANTITATIVE ASSAY; SENSITIVITY AND SPECIFICITY; WESTERN BLOTTING; BRAIN VENTRICLE; CEREBROSPINAL FLUID; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; ENZYMOLOGY; FOLLOW UP; METABOLISM;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CEREBRAL VENTRICLES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; LIPOCALINS; MALE; MULTIPROTEIN COMPLEXES; PREALBUMIN;

EID: 44949103387     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000312383.39973.88     Document Type: Article

References (40)

1. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 2004;1:213-225.
2. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
3. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56: 303-308.
4. National Institute on Aging and Reagan Institute. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol Aging 1997;18 (S4): S1-S2.
5. Markesbery WR, Schmitt FA, Kryscio RJ, Davis DG, Smith CD, Wekstein DR. Neuropathologic substrate of mild cognitive impairment. Arch Neurol 2006;63:38- 46.
6. Murrell JR, Schoner RG, Liepnieks JJ, Rosen HN, Moses AC, Benson MD. Production and functional analysis of normal and variant recombinant human transthyretin proteins. J Biol Chem 1992;267:16595- 16600.
7. Davidsson P, Sjogren M. Proteome studies of CSF in AD patients. Mech Ageing Dev 2006;127:133-137.
8. Biroccio A, Del Boccio P, Panella M, et al. Differential post-translational modifications of transthyretin in Alzheimer's disease: a study of the cerebral spinal fluid. Proteomics 2006;6:2305-2313.
9. Montine TJ, Montine KS, McMahan W, Markesbery WR, Quinn JF, Morrow JD. F2-isoprostanes in Alzheimer and other neurodegenerative diseases. Antioxid Redox Signal 2005;7:269-275.
10. Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH. Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann Neurol 2007;61:120-129.
11. Harrington MG, Fonteh AN, Biringer RG, Af RH, Cowan RP. Prostaglandin D synthase isoforms from cerebrospinal fluid vary with brain pathology. Dis Markers 2006;22:73-81.
12. Kanaoka Y, Ago H, Inagaki E, et al. Cloning and crystal structure of hematopoietic prostaglandin D synthase. Cell 1997;90:1085-1095.
13. Urade Y, Watanabe K, Hayaishi O. Prostaglandin D, E, and F synthases. J Lipid Mediat Cell Signal 1995;12: 257-273.
14. Christ-Hazelhof E, Nugteren DH. Purification and characterisation of prostaglandin endoperoxide D-isomerase, a cytoplasmic, glutathione-requiring enzyme. Biochim Biophys Acta 1979;572:43-51.
15. Nagata A, Suzuki Y, Igarashi M, et al. Human brain prostaglandin D synthase has been evolutionarily differentiated from lipophilic-ligand carrier proteins. Proc Natl Acad Sci USA 1991;88:4020-4024.
16. Giacomelli S, Leone MG, Grima J, Silvestrini B, Cheng CY. Astrocytes synthesize and secrete prostaglandin D synthetase in vitro. Biochim Biophys Acta 1996;1310: 269-276.
17. Clausen J. Proteins in normal cerebrospinal fluid not found in serum. Proc Soc Exp Biol Med 1961;107:170- 172.
18. Hayaishi O, Urade Y. Prostaglandin D2 in sleep-wake regulation: recent progress and perspectives. Neuroscientist 2002;8:12-15.
19. Taniike M, Mohri I, Eguchi N, Beuckmann CT, Suzuki K, Urade Y. Perineuronal oligodendrocytes protect against neuronal apoptosis through the production of lipocalin-type prostaglandin D synthase in a genetic demyelinating model. J Neurosci 2002;22:4885-4896.
20. Yamashima T, Sakuda K, Tohma Y, et al. Prostaglandin D synthase (beta-trace) in human arachnoid and meningioma cells: roles as a cell marker or in cerebrospinal fluid absorption, tumorigenesis, and calcification process. J Neurosci 1997;17:2376-2382.
21. Kanda Y, Goodman DS, Canfield RE, Morgan FJ. The amino acid sequence of human plasma prealbumin. J Biol Chem 1974;249:6796-6805.
22. Dickson PW, Howlett GJ, Schreiber G. Rat transthyre-tin (prealbumin). Molecular cloning, nucleotide sequence, and gene expression in liver and brain. J Biol Chem 1985;260:8214-8219.
23. Terazaki H, Ando Y, Nakamura M, et al. Variant transthyretin in blood circulation can transverse the blood-cerebrospinal barrier: qualitative analyses of transthyretin metabolism in sequential liver transplantation. Transplantation 2001;72:296-299.
24. Hagen GA, Elliott WJ. Transport of thyroid hormones in serum and cerebrospinal fluid. J Clin Endocrinol Metab 1973;37:415-422.
25. Sickmann A, Dormeyer W, Wortelkamp S, Woitalla D, Kuhn W, Meyer HE. Towards a high resolution separation of human cerebrospinal fluid. J Chromatogr B Analyt Technol Biomed Life Sci 2002;771:167-196.
26. Ingenbleek Y, Young V. Transthyretin (prealbumin) in health and disease: nutritional implications. Annu Rev Nutr 1994;14:495-533.
27. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583-596.
28. Quintas A, Saraiva MJ, Brito RM. The tetrameric protein transthyretin dissociates to a non-native monomer in solution: a novel model for amyloidogenesis. J Biol Chem 1999;274:32943-32949.
29. Saraiva MJ. Transthyretin amyloidosis: a tale of weak interactions. FEBS Lett 2001;498:201-203.
30. Quintas A, Vaz DC, Cardoso I, Saraiva MJ, Brito RM. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J Biol Chem 2001;276:27207-27213.
31. Reixach N, Deechongkit S, Jiang X, Kelly JW, Buxbaum JN. Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci USA 2004;101:2817-2822.
32. Merched A, Serot JM, Visvikis S, Aguillon D, Faure G, Siest G. Apolipoprotein E, transthyretin and actin in the CSF of Alzheimer's patients: relation with the senile plaques and cytoskeleton biochemistry. FEBS Lett 1998;425:225-228.
33. Schwarzman AL, Gregori L, Vitek MP, et al. Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci USA 1994;91: 8368-8372.
34. Serot JM, Christmann D, Dubost T, Couturier M. Cerebrospinal fluid transthyretin: aging and late onset Alzheimer's disease. J Neurol Neurosurg Psychiatry 1997;63:506-508.
35. Nakanishi T, Sato T, Sakoda S, Yoshioka M, Shimizu A. Modification of cysteine residue in transthyretin and a synthetic peptide: analyses by electrospray ionization mass spectrometry. Biochim Biophys Acta 2004;1698:45-53.
36. Suhr OB, Svendsen IH, Ohlsson PI, et al. Impact of age and amyloidosis on thiol conjugation of transthyretin in hereditary transthyretin amyloidosis. Amyloid 1999; 6:187-191.
37. Stein TD, Anders NJ, DeCarli C, Chan SL, Mattson MP, Johnson JA. Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APPSW mice resulting in tau phosphorylation and loss of hippocampal neurons: support for the amyloid hypothesis. J Neurosci 2004; 24:7707-7717.
38. Lescuyer P, Gandini A, Burkhard PR, Hochstrasser DF, Sanchez JC. Prostaglandin D2 synthase and its post-translational modifications in neurological disorders. Electrophoresis 2005;26:4563-4570.
39. Markesbery WR, Lovell MA. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 1998;19:33-36.
40. Williams TI, Lynn BC, Markesbery WR, Lovell MA. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease. Neurobiol Aging 2006;27:1094-1099.